Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer-Reference-Cited by-同舟云学术

Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

Published:2010-02-24 Issue:3 Volume:19 Page:333-341
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Hosmer Wylie,Malin Jennifer,Wong Mitchell

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.springerlink.com/index/pdf/10.1007/s00520-010-0821-1

Reference33 articles.

1. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

2. Glaspy JHJ, Flyer R et al (2001) Febrile Neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 98:432

3. Talcott J, Siegel R, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322

4. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170

5. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in the use of granulocyte colony stimulating factors for older patients with cancer, 2010 to 2019;Journal of Geriatric Oncology;2024-09

2. Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy;Cancer Investigation;2024-07-04

3. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative;Supportive Care in Cancer;2023-10-13

4. Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study;Int. Journal of Clinical Pharmacology and Therapeutics;2023-09-01

5. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis;BJU International;2023-07-03